S&P 500
3,376.83+3.40(+0.10%)Nasdaq
11,022.90-19.61(-0.18%)Russell 2000
1,580.43+0.64(+0.04%)
Altimmune, Inc. (ALT)
Chart Events
Performance Outlook
| Previous Close | 23.70 |
| Open | 24.17 |
| Bid | 24.33 x 800 |
| Ask | 24.48 x 900 |
| Day's Range | 23.03 - 24.46 |
| 52 Week Range | 1.51 - 35.10 |
| Volume | 363,217 |
| Avg. Volume | 5,372,256 |
| Market Cap | 804.181M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings Date | Nov 11, 2020 - Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 20, 2017 |
| 1y Target Est | 47.67 |
- GlobeNewswire
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update. “We are pleased with Altimmune’s progress during 2020 as we have launched two new product candidates for COVID-19, progressed our NASH candidate toward clinical testing and forged strategic alliances with Vigene Biosciences and DynPort Vaccine Company” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “With the support of our shareholders, we now have more than $200 million of cash and investments on hand to drive continued development of our product pipeline.”Recent Highlights * Received gross proceeds of $199.4 million from a public offering, warrant exercises and ATM sales since Q1 2020 Since the first quarter, the Company has received $132.2 million in gross proceeds from a public offering of common stock and pre-funded warrants, $40.9 million from warrant exercises and $26.3 million in gross proceeds from ATM sales. The cash received will be used primarily for the development of AdCOVID and T-COVID, including scale up of manufacturing and advanced clinical trials; the continued development of ALT-801, a dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH), including the first-in-human trial later this year; and for capital expenditures and general working capital purposes. * Announced positive preclinical results for AdCOVID The Company announced positive results from the preclinical studies of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. The studies, which were conducted in collaboration with the University of Alabama at Birmingham (UAB), showed strong serum neutralizing activity and potent mucosal immunity in the respiratory tract. The induction of mucosal IgA antibody in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19. Based on these findings, the Company has initiated manufacturing of AdCOVID and plans to advance the vaccine candidate to a Phase 1 safety and immunogenicity study in Q4 of this year. * Announced manufacturing agreement with Vigene Biosciences for AdCOVID The Company announced that it has entered into an agreement with Vigene Biosciences to manufacture AdCOVID, the Company’s single-dose intranasal vaccine candidate for COVID-19. Vigene, a Rockville, Maryland-based award-winning Contract Development and Manufacturing Organization, specializes in viral vectors and will deploy its capabilities to manufacture AdCOVID. Following recent positive pre-clinical data, the Company plans to start a Phase 1 clinical trial of AdCOVID in Q4 2020. * Formed teaming agreement with DynPort Vaccine Company for AdCOVID The Company announced that it has entered into a teaming agreement with DynPort Vaccine Company (DVC), a General Dynamics Information Technology (GDIT) company, to coordinate U.S. Government funding efforts and, if successful, to provide program management, drug development activity integration, and regulatory support for AdCOVID. * Initiated T-COVID program and received $4.7 million award from the DoD to fund Phase 1/2 clinical trial The U.S. Food and Drug Administration (FDA) authorized the Company to proceed with a Phase 1/2 clinical trial of T-COVID, an investigational therapeutic agent for the treatment of early COVID-19. The EPIC Trial (Efficacy and Safety of T-COVID in the Prevention of Clinical Worsening in COVID-19) is being funded through a $4.7 million competitive award from the U.S. Army Medical Research & Development Command (USAMRDC) and Department of Defense (DoD) working in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium. Altimmune recently initiated multiple clinical sites across the United States and expects that enrollment will commence imminently. * Completed enrollment in Phase 1b clinical trial of NasoShield The Company completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised. At the conclusion of the Phase 1b NasoShield trial, BARDA will have the option of exercising the remaining contract options valued at approximately $105 million to enable Phase 2 development. * Advanced IND-enabling activities for ALT-801 GLP-1/glucagon dual receptor agonist for NASH The Company has successfully completed the in-life portion of the safety and toxicological assessment of ALT-801 and is manufacturing the clinical trial material for the first-in-human trial, expected to start in Q4 2020. The single and multiple ascending dose trial will be conducted in Australia and will evaluate the safety and activity of ALT-801 in overweight and obese volunteers. Data from that study, including validation of the compound’s weight loss and liver fat-reducing effects, is expected to read out in the spring of 2021. * Received HepTcell IND clearance for Phase 2 trial The FDA cleared the Company’s Investigational New Drug (IND) application to conduct a Phase 2 trial of HepTcell, a peptide-based immunotherapeutic for the treatment of chronic hepatitis B (HBV). The Company is also filing CTAs in Canada and three European countries. Altimmune plans to initiate the multinational trial in Q4 of this year, subject to an ongoing assessment of the impact of COVID-19 on study conduct.Financial Results for the Second Quarter Ended June 30, 2020 * The Company had cash, cash equivalents and short-term investments of $80.3 million at June 30, 2020. Subsequent to the quarter ended June 30, 2020, the Company received approximately $136.2 million in net proceeds from the public offering of its common stock, warrant exercises, and ATM sales. * Revenue was $0.7 million for the quarter ended June 30, 2020 compared to $1.6 million in the prior year period. The change was primarily due to a decrease in billings under the Company’s U.S. government contracts due to timing of manufacturing and clinical trials for the NasoShield program. * Research and development expenses were $16.5 million for the quarter ended June 30, 2020 compared to $2.9 million in the prior year period. The increase was primarily attributable to an increase in the contingent liability for stock-based milestone payments associated with the acquisition of ALT-801; development costs for IND-enabling preclinical studies for ALT-801; and development costs for the COVID-19 programs. These increases were partially offset by decreased spend on the NasoShield program. * General and administrative expenses were $2.5 million for the quarter ended June 30, 2020 compared to $2.2 million in the prior year period. The increase is attributable to higher employee compensation and legal costs. * Income tax benefit was $1.6 million for the three months ended June 30, 2020, as compared to zero for the same period in 2019. The increase is attributable to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) passed on March 27, 2020 which made temporary changes regarding the utilization and carry back of net operating losses. The Company intends to file a tax refund claim with the Internal Revenue Service reflecting a partial refund of its 2016 tax liability by carrying back net operating losses arising during the three and six months ended June 30, 2020. * Net loss attributed to common stockholders for the quarter ended June 30, 2020 was $16.8 million, or $0.94 net loss per share, compared to $3.4 million in the prior year, or $0.26 net loss per share. The difference in net loss is primarily attributable to higher research and development expenses, lower revenue, offset by an increase in income tax benefit.Conference Call Information Altimmune will host a conference call to discuss the company’s second quarter results and other business information. Date: Wednesday, August 12, 2020 Time: 8:30 am Eastern Time Domestic: 877-423-9813 International: 201-689-8573 Conference ID: 13706947 Webcast: http://public.viavid.com/index.php?id=140748 Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The company has used, and intends to continue to use, the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, statements regarding the impact of COVID-19 on our business operations, clinical trials and results of operations, the timing of key milestones for our clinical assets, the development of our AdCOVID vaccine product candidate and initiation of animal testing in Q2 2020 and a Phase 1 clinical study in Q4 2020 for AdCOVID, the initiation of a Phase 1 clinical study in Q4 2020 for ALT-801 and receipt of data from this clinical study in 2021, the initiation of a Phase 2 clinical trial for HepTcell in Q4 2020, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; funding delays, reductions in or elimination of U.S. government funding and/or non-renewal of expiring funding under the Company’s agreement with Biomedical Advanced Research and Development Authority (“BARDA”), or the Company’s contract with the National Institutes of Allergy and Infectious Diseases (“NIAID”); the Company’s ability to satisfy certain technical milestones under the Company’s contracts with BARDA and NIAID that would entitle the Company to receive additional funding over the period of the agreement; the receipt of future potential payments under government contracts or grants; the Company’s ability to obtain potential regulatory approvals on the timelines anticipated, or at all; the Company’s ability to obtain additional patents or extend existing patents on the timelines anticipated, or at all; the Company’s ability to identify and consummate potential future strategic partnerships; and the Company’s ability to expand its pipeline of products and the success of future product advancements, including the success of future clinical trials, and the Company’s ability to commercialize its products. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, which are available at www.sec.gov.Investor Contacts: Will Brown Chief Financial Officer Phone: 240-654-1450 wbrown@altimmune.com Ashley R. Robinson LifeSci Advisors, LLC 617-430-7577 arr@lifesciadvisors.comMedia Contact: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com ALTIMMUNE, INC. CONSOLIDATED BALANCE SHEETS June 30, 2020 December 31, 2019 (unaudited) ASSETS Current assets: Cash and cash equivalents $64,741,921 $8,962,686 Restricted cash 34,174 34,174 Total cash, cash equivalents and restricted cash 64,776,095 8,996,860 Short-term investments 15,484,402 28,277,386 Accounts receivable 1,182,099 1,021,179 Tax refund receivable 5,506,946 629,096 Prepaid expenses and other current assets 1,020,876 470,228 Total current assets 87,970,418 39,394,749 Property and equipment, net 1,024,640 1,104,208 Right of use asset 662,074 698,321 Intangible assets, net 12,785,655 12,732,195 Other assets 100,980 128,547 Total assets $102,543,767 $54,058,020 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $195,217 $18,232 Accrued expenses and other current liabilities 4,089,749 3,904,767 Notes payable 632,000 — Total current liabilities 4,916,966 3,922,999 Contingent consideration 16,390,000 2,750,000 Other long-term liabilities 1,715,024 1,864,875 Total liabilities 23,021,990 8,537,874 Commitments and contingencies (Note 14) Stockholders’ equity: Common stock, $0.0001 par value; 200,000,000 shares authorized; 2,635 1,508 26,553,957 and 15,312,381 shares issued; 26,553,886 and 15,312,167 shares outstanding at June 30, 2020 and December 31, 2019, respectively Additional paid-in capital 242,579,532 187,914,916 Accumulated deficit (158,028,687) (137,376,122) Accumulated other comprehensive loss, net (5,031,703) (5,020,156) Total stockholders’ equity 79,521,777 45,520,146 Total liabilities and stockholders’ equity $102,543,767 $54,058,020 ALTIMMUNE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) For the Three Months Ended For the Six Months Ended June 30,June 30, 2020 2019 2020 2019 Revenues $721,636 $1,626,029 $2,934,330 $4,581,622 Operating expenses: Research and development 16,594,250 2,945,096 23,781,781 6,162,768 General and administrative 2,545,356 2,231,817 4,877,273 4,298,299 Total operating expenses 19,139,606 5,176,913 28,659,054 10,461,067 Loss from operations (18,417,970) (3,550,884) (25,724,724) (5,879,445) Other (expense) income: Changes in fair value of warrant liability — (46,000) — (46,000) Interest expense (3,308) (748) (5,193) (1,488) Interest income 81,458 239,964 233,027 425,211 Other (expense) income, net (5,878) (29,220) 19,664 17,528 Total other (expense) income, net 72,272 163,996 247,498 395,251 Net loss before income tax benefit (18,345,698) (3,386,888) (25,477,226) (5,484,194) Income tax benefit 1,578,782 — 4,824,661 — Net loss (16,766,916) (3,386,888) (20,652,565) (5,484,194) Other comprehensive loss – unrealized gain (loss) on investments 20,888 — (11,547) — Comprehensive loss $(16,746,028) $(3,386,888) $(20,664,112) $(5,484,194) Net loss $(16,766,916) $(3,386,888) $(20,652,565) $(5,484,194) Deemed dividends — — — (452,925) Net loss attributed to common stockholders $(16,766,916) $(3,386,888) $(20,652,565) $(5,937,119) Net loss per share attributed to common stockholders, basic and diluted $(0.94) $(0.26) $(1.25) $(0.52) Weighted-average common shares outstanding, basic and diluted 17,886,853 13,127,773 16,498,719 11,318,819
- GlobeNewswire
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020. The clinical trial has enrolled 42 evaluable healthy subjects to receive intranasally administered NasoShield or placebo and be followed for 6 months following dosing. The primary immunogenicity readouts are the serum antibody response to protective antigen and toxin-neutralizing antibody titer 28 and 56 days after dosing. As with Altimmune’s other vaccine programs, stimulation of a mucosal IgA immune response in the nasal cavity will also be assessed as a potential additional benefit to other immunologic responses. Nasal mucosal immunity, which can play an important role in the body’s defense against respiratory diseases, is best stimulated by the nasal route of vaccine administration.The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised. At the conclusion of the Phase 1b NasoShield trial, BARDA will have the option of exercising the remaining contract options valued at approximately $105 million to enable Phase 2 development.NasoShield has the potential to be a convenient and simple alternative to the current approved multi-dose anthrax vaccine, as it is intended to confer protection after a single intranasal dose instead of the three-injection regimen required by the only licensed vaccine. Intranasal dosing provides the potential to be administered rapidly and without the need for needles, syringes or trained healthcare personnel in the event of an anthrax incident. In addition, NasoShield’s expected room temperature stability profile may allow for broad distribution of the vaccine without the need for expensive cold-chain logistics, such as refrigeration or freezing.Earlier this quarter, the Company reported positive preclinical data on AdCOVID, a single dose intranasal COVID-19 vaccine candidate which is derived from the same replication-deficient adenovirus 5 vaccine platform technology as NasoShield. In these preclinical studies performed in collaboration with the University of Alabama at Birmingham (UAB), AdCOVID elicited a strong systemic antibody response against the receptor-binding domain (RBD) in mice, stimulated serum viral neutralization titers, and activated a 29-fold induction of mucosal IgA against SARS-CoV-2 in bronchoalveolar fluid of vaccinated mice. The Company plans to initiate a Phase 1 clinical trial of AdCOVID during the fourth quarter of 2020.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the initiation and timing of the NasoShield clinical trial and receipt of data from the clinical trial in 2020, the potential for additional funding from BARDA, the potential immunization effects of NasoShield, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; funding delays, reductions in or elimination of U.S. government funding and/or non-renewal of expiring funding under the Company’s agreement with BARDA; the Company’s ability to satisfy certain technical milestones under the Company’s contracts with BARDA that would entitle the Company to receive additional funding over the period of the agreement; the Company’s ability to obtain potential regulatory approvals on the timelines anticipated, or at all; and the Company’s ability to expand its pipeline of products and the success of future product advancements, including the success of future clinical trials, and the Company’s ability to commercialize its products. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 and quarterly report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC, which are available at www.sec.gov.Investor Contacts: Will Brown Ashley R. Robinson Chief Financial Officer LifeSci Advisors, LLC Phone: 240-654-1450 617-430-7577 wbrown@altimmune.com arr@lifesciadvisors.com Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com
- GlobeNewswire
Altimmune to Announce Second Quarter 2020 Financial Results on August 12
GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference call on Wednesday, August 12, 2020. Conference Call Details Date:Wednesday, August 12 Time:8:30 am Eastern Time Domestic:877-423-9813 International:201-689-8573 Conference ID:13706947 Webcast:http://public.viavid.com/index.php?id=140748 About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Investor Contacts: Will BrownAshley R. Robinson Chief Financial OfficerLifeSci Advisors, LLC Phone: 240-654-1450617-430-7577 wbrown@altimmune.comarr@lifesciadvisors.com Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com
